You are here: Industry Insights > Humira

News List

NHS set to save record £300 million on highest drug spend contractpharma
November 28, 2018
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira (adalimumab) firstwordpharma
November 14, 2018
Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a world-class China-based biopharmaceutical company that develops
AbbVie announces global patent license with Momenta biospectrum
November 08, 2018
Momenta's U.S. license will begin on November 20, 2023, and will not be accelerated by the entry of companies who have already taken a license.
AbbVie offers up 80% Humira discount in EU tender market to hold off biosimilars: report fiercepharma
November 02, 2018
How far is AbbVie willing to go to fend off the new Humira biosimilars in Europe? Quite far, apparently, judging by the enormous discount it offered to win a government contract.
Biosimilars of the “Drug King” Humira being marketed, eroding the Global Sales of the Original Drug! Zhixing
October 25, 2018
Humira is a well-deserved drug king as it had been staying on the position of top of global best-selling drugs for six c
Amgen begins rolling out Humira biosimilar in the EU pharmatimes
October 19, 2018
Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.
Another Humira biosimilar hits EU shores pharmatimes
October 19, 2018
Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.
AbbVie inks yet another Humira biosim deal—this time with Novartis—as EU launches near fiercepharma
October 15, 2018
AbbVie has already inked several patent settlements with biosimilar developers looking to take on its megablockbuster Humira, and now the company is back at the deal table with a fourth.
EU green light for new Humira biosimilar pharmatimes
September 27, 2018
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
EU green light for new Humira biosimilar pharmatimes
September 21, 2018
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.

Previous page 1 2 3 4 5 6 7 Next page